-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
HBV-IN-19
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2241575-59-5.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 2241575-59-5 |
| Description | HBV-IN-19 inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection. |
Product Information
| Synonyms | HBV-IN-19|SCHEMBL20463669|HY-145713|CS-0379821 |
| Molecular Weight | 442.5 |
| Molecular Formula | C24H30N2O6 |
| Canonical SMILES | CC1(CCC2N1N3C=C(C(=O)C=C3C4=C2C=C(C(=C4)COC)OCCCOC)C(=O)O)C |
| Purity | ≥98% (HPLC) |
| Solubility | 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 806 |
| Exact Mass | 442.21038668 |
| Target | HBV |
| XLogP3-AA | 0.7 |
